Clinical trials
Basal Cell Carcinoma clinical trials
Below are recruiting basal cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 318 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07465276RecruitingPhase 2
Two immunotherapies before surgery for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (ficerafusp alfa and pembrolizumab) given before surgery for advanced head and neck cancer that can be removed. The goal is to see if this approach can shrink the tumor and improve outcomes.
Boston, MassachusettsAges 18 years+ - NCT07312578Enrolling by invitationPhase 2
Targeted drugs plus chemo before surgery for esophageal cancer
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18–70 - NCT07290010RecruitingPhase 2
Iparomlimab plus chemotherapy for advanced esophageal cancer
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) with chemotherapy as a first treatment for advanced esophageal squamous cell carcinoma. It aims to see if this combination is safe and effective for people whose cancer cannot be removed by surgery or has spread.
Shijiazhuang, HebeiAges 18 years+ - NCT07219576RecruitingPhase 1/Phase 2
Study of Retifanlimab and Ruxolitinib for Certain Cancers
This trial tests a combination of two drugs, retifanlimab and ruxolitinib, for people with advanced kidney cancer (clear cell renal cell carcinoma) or lung cancer (non-small cell lung carcinoma) whose cancer has grown after previous treatment with a type of immunotherapy called PD-1/PD-L1 inhibitors. The goal is to see if this combination can help when standard treatments are no longer working.
La Jolla, CaliforniaAges Any age - NCT07080437Recruiting
Immunotherapy and chemoradiation for elderly esophageal cancer patients
This study looks at how safe and effective a combination of immunotherapy (a treatment that helps your immune system fight cancer) and standard chemotherapy plus radiation is for older adults (70+) with a type of esophageal cancer called squamous cell carcinoma who cannot have surgery or choose not to.
Chongqing, Chongqing MunicipalityAges 70 years+ - NCT06988956RecruitingPhase 2
Nimotuzumab Plus Chemoradiation for Older Adults with Esophageal Cancer
This trial tests adding nimotuzumab, a targeted therapy, to standard chemoradiation for elderly patients with esophageal squamous cell cancer. It aims to see if the combination improves outcomes.
NanjingAges 75 years+ - NCT07039162RecruitingPhase 2
Tislelizumab with chemo and radiation before surgery for advanced esophageal cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
Kaohsiung CityAges 20 years+ - NCT07002346RecruitingPhase 3
Immunotherapy and bevacizumab for advanced ovarian clear cell cancer
This trial tests a combination of an immunotherapy drug (QL1706) and a targeted therapy (bevacizumab) for women with newly diagnosed advanced ovarian clear cell carcinoma. The goal is to see if this combination works better than standard treatment after surgery.
Wuhan, HubeiAges 18–75 - NCT06912074RecruitingPhase 2
Comparing shorter vs. longer radiation after chemo-immunotherapy for esophageal cancer
This trial tests if a shorter course of radiation is as effective as the standard longer course after initial chemotherapy plus immunotherapy in people with advanced esophageal cancer that cannot be surgically removed.
Guangzhou, GuangdongAges 18–80 - NCT06585410RecruitingPhase 3
Cemiplimab injection for early-stage skin cancer
This trial tests a drug (cemiplimab) injected directly into early-stage skin cancer (squamous cell carcinoma) to see if it can shrink or cure the cancer before surgery. It may help patients avoid more extensive surgery or reduce the chance of the cancer coming back.
Phoenix, ArizonaAges 18 years+ - NCT06567314RecruitingPhase 2
Study of Ivonescimab for advanced skin or prostate cancer
This study tests a new immunotherapy medicine, ivonescimab, in people with advanced skin cancer or advanced prostate cancer. It looks at how safe and effective the drug is.
Houston, TexasAges 18 years+ - NCT06288191RecruitingPhase 2
Nivolumab and relatlimab before surgery for skin cancer
This trial tests if two immunotherapy drugs, nivolumab and relatlimab, given before surgery can help shrink a type of skin cancer called cutaneous squamous cell carcinoma. It's for people whose cancer can be removed with surgery.
Wollstonecraft, New South WalesAges 18 years+ - NCT06005818RecruitingPhase 2
MRD-guided therapy for kidney cancer after surgery
This trial tests whether personalized monitoring of cancer DNA in your blood (MRD) can guide treatment decisions after kidney cancer surgery. If MRD is detected, you may receive extra immunotherapy to reduce the risk of cancer returning.
Birmingham, AlabamaAges 18 years+ - NCT06048926Enrolling by invitation
Carrelizumab with chemoradiation for advanced esophageal cancer
This trial tests combining the immunotherapy drug carrelizumab with standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this combination can help shrink or control the tumor.
NanjingAges 18–75 - NCT05473156RecruitingPhase 1/Phase 2
Study of AP203 for advanced solid tumors that grew despite treatment
This early-phase study tests AP203 (an investigational treatment) to see if it is safe and to look for signs it can shrink or control certain advanced cancers. The study includes a dose-finding part for many solid tumors, and a second part focused on specific lung and head/neck cancers that previously received PD-1/PD-L1 therapy.
TaipeiAges 18 years+ - NCT06342167RecruitingPhase 2
Immunotherapy and radiation with nutrition support for esophageal cancer
This trial combines an immunotherapy drug (a PD-1 inhibitor) with radiation therapy and special nutrition drinks to treat esophageal cancer that cannot be removed with surgery. The goal is to see if this combination is safe and effective in helping patients live longer and feel better.
Beijing, Beijing MunicipalityAges 18–80 - NCT07333274RecruitingPhase 3
Radiation plus nimotuzumab for head and neck cancer
This trial compares radiation therapy alone versus radiation therapy plus a targeted drug called nimotuzumab for people with advanced head and neck cancer who cannot take cisplatin chemotherapy. The goal is to see if adding nimotuzumab improves outcomes.
Shandong, ProvinceAges 18 years+ - NCT05173246RecruitingPhase 2
First-line treatment study for advanced small cell esophageal cancer
This Phase 2 trial tests JS001 plus TP as a first treatment for people with advanced or unresectable small cell esophageal cancer. It aims to see how well this combination controls the cancer and improves outcomes compared with starting treatment with standard options.
Guangzhou, GuangdongAges 18–75 - NCT06515990RecruitingPhase 1/Phase 2
DM005 for Advanced Solid Tumors
This study tests a new drug called DM005 for people with advanced solid tumors (like lung, stomach, colon, liver, pancreas, or head and neck cancer) that have not responded to or can't tolerate standard treatments. The goal is to see if DM005 is safe and how well it works.
Detroit, MichiganAges 18 years+ - NCT06797986RecruitingPhase 1/Phase 2
Vaccine for HPV-positive head and neck cancer
This trial tests an investigational vaccine called BVAC-E6E7 for head and neck cancer caused by HPV types 16 or 18 that has come back or spread. It is for people who have already tried standard treatments like platinum chemo or immunotherapy, or can't take them.
SeoulAges 19 years+ - NCT06473103Recruiting
Checking skin cancer margins with a new microscope
This trial is testing a new microscope technique that may help doctors see more clearly whether all cancer cells have been removed during standard skin cancer surgery. It could help make sure the surgery is successful the first time.
Victor, New YorkAges Any age - NCT06907095Recruiting
Early cancer detection study for high-risk individuals
This study tests if a simple blood or fluid test can find cancer early in people with a higher-than-average risk. If you have certain genetic mutations, a strong family history of cancer, or other high-risk conditions, you may be able to join.
VillejuifAges 18 years+ - NCT03050268Recruiting
Study of childhood cancer risk in families
This study looks at inherited (family) risk for childhood cancers, including families with early cancers or known cancer risk conditions. It may help researchers understand why some children get cancer and improve future risk detection and care.
Memphis, TennesseeAges Any age - NCT06354530RecruitingPhase 2/Phase 3
Study of pre-surgery therapy for advanced esophageal cancer
This trial tests a combination of drugs (anlotinib, immunotherapy, and chemotherapy) given before surgery for esophageal cancer that has not spread to other organs. The goal is to see if this approach shrinks the tumor and improves outcomes.
Chongqing, None SelectedAges 18–80
Hear when a new Basal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for basal cell carcinoma?
- Yes. Clin2 currently lists 318 recruiting basal cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a basal cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a basal cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.